FDA Licenses Merck’s Capvaxive Pneumococcal Vaccine
On June 17, 2024, the U.S. Food and Drug Administration (FDA) licensed Merck & Company, Inc.’s new pneumococcal conjugate vaccine Capvaxive (formerly V116) for adults 18 years of age and older. The vaccine is designed to protect against 21 types of the bacteria causing pneumococcal disease, which can lead to severe infection in the lungs […]
Researchers Found Variable Aluminum Content in Infant Vaccines Inaccurately Measured and Reported
Story Highlights Christopher Exley, PhD has hundreds of peer-reviewed articles and a well-established international reputation for his expertise on the toxicity and neurotoxicity of aluminum in the brain. In a study published in 2021, he and his colleagues investigating aluminum toxicity demonstrated that the amount of aluminum in vaccines varies and differs significantly from amounts […]
Pfizer Fined Again for Violating Drug Laws
Colombia’s national regulatory agency, the Superintendency of Industry and Commerce (SIC), has fined pharmaceutical company Pfizer $25,000 for allegedly inflating the price of several prescription drugs it sold in that country.1 2 On July 31, 2019, the agency stated: The decision was taken after verifying information related to PFIZER SAS’ commercial operations between July and December […]
